Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer
CHICAGO — Combining enzalutamide (Xtandi) with an androgen deprivation therapy (ADT) boosted metastasis-free survival (MFS) in patients with prostate cancer at high risk for biochemical recurrence, according to the EMBARK trial. After a median follow up of 60.7 months, the combination of enzalutamide and leuprolide acetate ADT demonstrated a 58% reduction in the risk of […]